Minocycline prevents oxidative protein modifications and damage in disease models associated with inflammatory glial activation and oxidative stress. Although the drug has been assumed to act by preventing the up-regulation of proinflammatory enzymes, we probed here its direct chemical interaction with reactive oxygen species. The antibiotic did not react with superoxide or $\cdot$NO radicals, but peroxynitrite (PON) was scavenged in the range of $\sim 1 \mu M$ minocycline and below. The interaction of pharmacologically relevant minocycline concentrations with PON was corroborated in several assay systems and significantly exceeded the efficacy of other antibiotics. Minocycline was degraded during the reaction with PON, and the resultant products lacked antioxidant properties. The antioxidative activity of minocycline extended to cellular systems, because it prevented neuronal mitochondrial DNA damage and glutathione depletion. Maintenance of neuronal viability under PON stress was shown to be solely dependent on direct chemical scavenging by minocycline. We chose $\alpha$-synuclein (ASYN), known from Parkinsonian pathology as a biologically relevant target in chemical and cellular nitration reactions. Submicromolar concentrations of minocycline prevented tyrosine nitration of ASYN by PON. Mass spectrometric analysis revealed that minocycline impeded nitration more effectively than methionine oxidations and dimerizations of ASYN, which are secondary reactions under PON stress. Thus, PON scavenging at low concentrations is a novel feature of minocycline and may help to explain its pharmacological activity.

Minocycline, a semisynthetic tetracycline derivative, has now been in clinical use for almost 40 years and is known for its excellent oral bioavailability and tissue distribution. Its efficient blood brain barrier passage (central nervous system/plasma distribution rate in the range of 0.3–0.6) allows central nervous system levels up to the micromolar range after repeated daily standard oral doses of 100–200 mg (1–3). In addition to its primary application as an antimicrobial agent, the use of minocycline has been considered in the field of neuroprotection (4, 5). Its tissue-protective properties have been demonstrated in animal models of stroke, amyotrophic lateral sclerosis, multiple sclerosis, and Parkinson, Alzheimer, and Huntington diseases (6–12).

Some direct neuroprotective actions of minocycline have been demonstrated in vivo (13, 14). Its beneficial in vivo activities have been suggested to be mainly based on its capacity to dampen glia activation and to reduce the tissue concentration of inflammatory mediators contributing to the degeneration process (11, 15–19). Accordingly, alterations of cell function by the antibiotic are best described for brain macrophages and microglial cells (20, 21). The majority of studies describe a reduced up-regulation of inflammatory components, such as surface markers, cytokines, or pro-inflammatory enzymes (22, 23). The reduced activity of enzymes such as nitric-oxide synthase or peroxidases is generally assumed to account for attenuated nitration of proteins caused by less peroxynitrite formation.

Apart from this hypothesis on indirect anti-inflammatory effects, relatively little information is available on the biochemical mode of action of minocycline. It has been argued that different targets are relevant in different settings, as suggested by largely varying effective concentrations of the drug (12, 16, 24, 25). Many studies observed an effect of the antibiotic on phosphorylation and hence the activation status of p38 MAPK, and a correlation of reduced p38 MAPK activation with the observed protective/anti-inflammatory effect was shown (12, 26). Other studies focused on a potential role of matrix metalloproteinase inhibition in the actions of minocycline (13, 27). However, a biochemically or pharmacologically defined target has not been characterized in any model system so far.

The difficulty of finding a protein-binding partner may be explained if minocycline acted by stoichiometric reaction with small molecules and thereby affected a multitude of processes indirectly. Such observations have been made earlier with other widely used drugs such as the analgesic acetaminophen, which has been demonstrated to act as selective scavenger of peroxynitrite (28). Because neurodegenerative diseases are always accompanied by inflammatory conditions (29), the potentially combined direct (on neurons) and indirect actions (prevention of detrimental inflammatory mediator synthesis) of minocycline would explain the good activity seen in animal models of disease. Reactive oxygen species generated in many cells under such conditions comprise $H_2O_2$, the hydroxyl radical (‘OH), nitric oxide (‘NO), superoxi-
ide ($O_2^\cdot$), and peroxynitrite (ONO$O^-$). The latter anion or the decomposition products (‘NO$_2$ and ‘OH) of its protonated form, respectively, can modify the structure and function of proteins and enzymes by nitration of tyrosine residues or by methionine sulfoxidation (30, 31). Prominent examples of signal transduction systems regulated by peroxynitrite are the methionine sulfoxidation (30, 31). Prominent examples of form, respectively, can modify the structure and function of

Minocycline as Scavenger of Peroxynitrite

Carlsbad, CA), and L-012 was from Wako (Neuss, Germany). Dihydrorhodamine 123 superoxide dismutase, KO$_2$, and AAPH (2,2’-genteamicin, rifampicin, ascorbic acid, uric acid, copper zinc-superoxide dismutase were from Sigma, and 4-dimethylaminophenol was from Cayman Chemicals (Ann Arbor, MI). Dihydrorhodamine 123 was investigated by the use of the ‘NO-releasing compound Spermine-NONOate (10 μM) and an ‘NO-electrode (Ami NO-700; Innovative Instruments, Tampa, FL) in 10 mM potassium phosphate buffer, pH 7.4. The electrode was calibrated every day with NaNO$_2$ standards in 0.1 M H$_2$SO$_4$ plus 100 μM potassium iodide. The current difference between base-line buffer signal and the peak following the addition of NaNO$_2$ served for calibration of the instrument. The measurements were performed in stirred glass tubes at 37 °C.

Superoxide ($O_2^\cdot$) Detection by the Cytochrome c Assay—Xanthine oxidase (1 milliunit/ml) plus hypoxanthine (500 μM) in 10 mM potassium phosphate, pH 7.4, were used as a radical generating system. In the presence of test compounds, the reduction of cytochrome c (50 μM) was measured by a spectrophotometer at 550 nm in 3-min intervals over a period of 20 min. The samples were incubated in the presence or absence of copper zinc-superoxide dismutase (100 units/ml); the O$_2^\cdot$-dependent part was calculated from the difference between the two corresponding measurements.

Hydroxyl (‘OH) Radical Generation—Hydroxyl radicals were generated by a combination of ferrous iron (Fe$^{2+}$) and H$_2$O$_2$ and detected by measurement of the formation of chromogens (at 532 nm) that originate from the interaction of deoxyribose degradation products with thiobarbituric acid. One hundred μl of a 150 mM NaCl solution (pH 7.4) were combined freshly with 50 μl of 0.7 mM EDTA, 50 μl of 0.5 mM Fe$^{2+}$ and 100 μl of sample in water. Hydroxyl radical generation was then initiated by the addition of 50 μl of 0.5 mM H$_2$O$_2$. The mixture was incubated with additional 100 μl of 5 mM 2-deoxyribose for 20 min at 37 °C under gentle shaking. Then 250 μl of 1% thiobarbituric acid (in 50 mM NaOH) and 250 μl of 2.8% trichloroacetic acid (in water) were added, vortexed thoroughly, shortly centrifuged to remove debris, and read at 532 nm.

HPLC Analysis—Detection of minocycline was performed on a Kontron system (Goebel Analytik, Au/Hallertau, Germany) composed of a model 560 autosampler, a model 520 pump unit, and a model 535 diode array detector set at 350 nm. Separation was carried out on a C8 nucleosil column (250 × 4 mm; 5-μm particle size) from Machery Nagel (Düren, Germany) at room temperature. The mobile phase for minocycline analysis consisted of acetonitrile:methanol:water: trifluoroacetic acid (25: 2: 72.9: 0.1, v/v, pH 1.76). Before use, the mobile phase was degassed and delivered isocratically at a flow rate of 0.8 ml/min at an average pressure of 140 bar. Data

EXPERIMENTAL PROCEDURES

Materials—Sin-1 (3-morpholinosydnonimine) (peroxynitrite generator), Spermine-NONOate (nitric oxide donor), and authentic peroxynitrite (PON)$^2$ were purchased from Cayman Chemicals (Ann Arbor, MI). Dihydrorhodamine 123 (DHR 123) and TEMPO$^-$-H$^+$ were from Molecular Probes (Carlsbad, CA), and L-012 was from Wako (Neuss, Germany). Wild type α-synuclein (ASYN), minocycline, tetracycline, gentamicin, rifampicin, ascorbic acid, uric acid, copper zinc-superoxide dismutase were from Sigma, and 4-dimethylaminophenol was from Koehler Chemie (Bensheim, Germany). Sin-1 and Spermine-NONOate solutions were prepared freshly before each experiment. Photometric determinations of PON stock concentrations were performed routinely ($λ_{max}$ 302 nm; ε, 1670 liter mol$^{-1}$ cm$^{-1}$). PON was diluted in 0.3 M NaOH. When PON was used, an equal amount of equimolar HCl was added to the respective sample. In cell-free experiments, PON (in NaOH) and the corresponding volume of equimolar HCl were added carefully as separate droplets in the inner ring of a reaction tube, closed, and vortexed instantaneously and rigorously.

Radical Detection—The interaction between minocycline and PON was monitored by the oxidation of DHR 123 (1 μM)

or by the luminol derivate L-012 (100 μM) in 10 mM potassium phosphate buffer, pH 7.4, containing desferoxamine (100 μM, to prevent Fenton chemistry reactions), if not otherwise indicated. The radical generating systems were incubated with the test compounds for 5 min at 37 °C before the radical detection dyes DHR 123 or L-012 were added and incubated for 15 min. Both dyes were chosen, because they are relatively selective for steady state PON levels in the submicromolar range. DHR 123 fluorescence ($λ_{ex}$ = 485 nm, $λ_{em}$ = 538 nm) as well as L-012 luminescence were detected in 96-well plates using a TECAN Infinite M200 reader.

‘NO Detection—Interaction between ‘NO and minocycline was investigated by the use of the ‘NO-releasing compound Spermine-NONOate (10 μM) and an ‘NO-electrode (Ami NO-700; Innovative Instruments, Tampa, FL) in 10 mM potassium phosphate buffer, pH 7.4. The electrode was calibrated every day with NaNO$_2$ standards in 0.1 M H$_2$SO$_4$ plus 100 μM potassium iodide. The current difference between base-line buffer signal and the peak following the addition of NaNO$_2$ served for calibration of the instrument. The measurements were performed in stirred glass tubes at 37 °C.

Hydroxyl (‘OH) Radical Generation—Hydroxyl radicals were generated by a combination of ferrous iron (Fe$^{2+}$) and H$_2$O$_2$ and detected by measurement of the formation of chromogens (at 532 nm) that originate from the interaction of deoxyribose degradation products with thiobarbituric acid. One hundred μl of a 150 mM NaCl solution (pH 7.4) were combined freshly with 50 μl of 0.7 mM EDTA, 50 μl of 0.5 mM Fe$^{2+}$ and 100 μl of sample in water. Hydroxyl radical generation was then initiated by the addition of 50 μl of 0.5 mM H$_2$O$_2$. The mixture was incubated with additional 100 μl of 5 mM 2-deoxyribose for 20 min at 37 °C under gentle shaking. Then 250 μl of 1% thiobarbituric acid (in 50 mM NaOH) and 250 μl of 2.8% trichloroacetic acid in (water) were added, vortexed thoroughly, shortly centrifuged to remove debris, and read at 532 nm.

HPLC Analysis—Detection of minocycline was performed on a Kontron system (Goebel Analytik, Au/Hallertau, Germany) composed of a model 560 autosampler, a model 520 pump unit, and a model 535 diode array detector set at 350 nm. Separation was carried out on a C8 nucleosil column (250 × 4 mm; 5-μm particle size) from Machery Nagel (Düren, Germany) at room temperature. The mobile phase for minocycline analysis consisted of acetonitrile:methanol:water: trifluoroacetic acid (25: 2: 72.9: 0.1, v/v, pH 1.76). Before use, the mobile phase was degassed and delivered isocratically at a flow rate of 0.8 ml/min at an average pressure of 140 bar. Data

2 The abbreviations used are: PON, peroxynitrite; ASYN, α-synuclein; DHR 123, dihydorhodamine 123; AAPH, 2,2’-azobis[2-methyl-propionamidine] hydrochloride; 3-NT, 3-nitrotyrosine; LDH, lactate dehydrogenase; ANOVA, analysis of variance; LUHMES, Lund human mesencephalic cells.
analysis was performed with Geminyx II software (Goebel Analytik).

Detection of DNA Oxidation—Oxidative DNA base lesions (8-oxo-2′-deoxyguanosine) were converted into strand breaks by short incubation with formamidopyrimidine-DNA glycosylase. The DNA strand breaks were then measured by an automated fluorimetric detection of alkaline DNA unwinding assay described in detail previously (36, 37). The conditions were optimized to allow unwinding of DNA at sites of strand breaks, and the amount of double-stranded DNA was detected by measurement of ethidium bromide incorporation. As a DNA model system, a 14-kbp plasmid (pAcHLT-A-His6) produced in Escherichia coli DH5α cells was treated with minocycline, tetracycline, or gentamicin and 50 μM Sin-1 for 40 min. In each experiment, a full set of controls was run, including calibration controls, and omission of enzyme, challenge, or drug. The data are indicated as fractions of DNA in the unwound state.

Detection of the Common Deletion—Mitochondrial DNA damage following Sin-1 treatment of intact LUHMES cells was assessed by the detection of a 4977-bp deletion, termed common deletion (38). Total DNA of the cell homogenate (including mitochondrial DNA) was collected by extraction using a QIAamp DNA blood mini kit (Qiagen), total DNA content was measured by a Nanodrop 1000 Spectrophotometer (Peqlab, Erlangen, Germany) and adjusted to equal amounts. PCR was performed in 96-well format with a Bio-Rad MyIQ real time PCR apparatus. Amplification was performed using the Platinum® SYBR® Green qPCR SuperMix-UDG kit (Invitrogen). Data analysis was conducted by iCycler software (Bio-Rad), threshold cycles (Ct) were determined for each sample for evaluation. The following primers were used: common deletion forward, 5′-ATT CAG TAG TCT CTC ATT ACA CTA TTC TTT GCT GGC-3′; common deletion reverse, 5′-AAG GTA TAT TCC TCT GCA ATG CTA GTC GCC TGC TGC TGC-3′; internal standard forward, 5′-GAT TTC GTG GGT ACC ACC CAA GTA TTG-3′; and internal standard reverse, 5′-AAT ATT CAT GCT GTC TGG CAG CAG TA-3′. After an initial heating step of 1 min at 95 °C, 40 cycles of 15 s at 95 °C (denaturation) and 1 min at 60 °C (annealing and elongation) were run.

Cell Culture—LUHMES cells are conditionally immortalized human fetal ventral mesencephalic neuronal precursor cells that were clonally selected. Differentiated LUHMES show a clear dopaminergic phenotype that was described in detail previously (39, 40). The cells were propagated in Advanced DMEM/F-12 (Invitrogen), 1× N2 supplement (Invitrogen), 2 mM l-glutamine (Invitrogen), and 40 ng/ml recombinant bFGF (R & D Systems, Minneapolis, MN). The differentiation process was initiated by the addition of differentiation medium consisting of advanced DMEM/F-12, 1× N2 supplement, 2 mM l-glutamine, 1 mM dibutylryl-cAMP (Sigma), 1 μg/ml tetracycline (Sigma), and 2 ng/ml recombinant human glial derived neurotrophic factor (GDNF) (R & D Systems). After 2 days, the cells were trypsinized and collected in Advanced DMEM/F-12 medium. The cells were seeded onto 24-well plates at a density of 160,000 cells/cm². The differentiation process was continued for an additional 4 days. For the Sin-1/PON treatment experiments, differentia-
Minocycline as Scavenger of Peroxynitrite

Western Blot—ASYN from the nitration experiments was loaded onto a 12% SDS gel (0.1 μg/lane). The proteins were transferred onto nitrocellulose membranes (Amersham Biosciences) and blocked with 5% milk in PBS-Tween (0.1%) for 2 h. Monoclonal antibodies directed against ASYN (1:1000) (32-8100; Zymed Laboratories Inc./Invitrogen) or against 3-nitrotyrosine (3-NT) (1:250) (HBT, HM5001, Uden, The Netherlands) were incubated at 4 °C overnight. The horseradish peroxidase-conjugated secondary antibody (goat anti-mouse IgG; Jackson ImmunoResearch, West Grove, PA) was incubated for 45 min. For quantitative evaluation, luminescence was detected and quantified by a FUSION SL™ system (Peqlab, Erlangen, Germany).

Resazurin Metabolization Assay—Resazurin (Sigma) was added to the cell culture medium in a final concentration of 2.5 μg/ml. Fluorescence was measured in 30-min intervals (λex = 530 nm; λem = 590 nm) over a period of 3 h.

Lactate Dehydrogenase (LDH) Release Assay—LDH activity was detected separately in the supernatant and cell lysate. The cells were lysed in PBS with 0.5% Triton X-100 for 20 min. The percentage of LDH released was calculated as 100 × [LDHsupernatant/LDHsupernatant + lysate]. For the enzymatic assay, 10 μl of sample was added to 200 μl of reaction buffer containing NADH (100 μM) and sodium pyruvate (600 μM) in sodium phosphate buffer adjusted to pH 7.4 by 40.24 mM K2HPO4 and 9.7 mM KH2PO4 buffer. Absorption at 340 nm was detected at 37 °C in 1-min intervals over a period of 20 min, and enzyme activity was calculated from the slope.

EPR Measurements—EPR measurements were performed at 20 °C using a MiniScope spectrometer (MS200; Magnettech GmbH) equipped with a variable temperature unit (Temperature Controller TC-H02; Magnettech GmbH). The samples were loaded into glass capillaries (outer diameter, 1 mm) with typical sample volumes of 10 μl. The spectra were obtained in an X-band (9.44 GHz) with a modulation amplitude of 0.6 G, microwave attenuation 10 dB, and a sweep width of 100 G. The signal-to-noise ratio was improved by accumulation of 10 spectra featuring a 60-s scan time each.

Mass Spectroscopic Analysis—a-Synuclein samples were analyzed by reversed phase LC-MS/MS using an LTQ-Orbitrap mass spectrometer (Thermo Fisher) and an Eksigent nano-HPLC. The dimensions of the reversed phase LC column were 5 μm, 200-Å pore size C18 resin in a 75-μm inner diameter × 10-cm-long piece of fused silica capillary (Hypersil Gold C18; New Objective). After sample injection, the column was washed for 5 min with 95% mobile phase A (0.1% formic acid in water) and 5% mobile phase B (0.1% formic acid in acetonitrile), and the peptides were eluted using a linear gradient of 5% mobile phase B to 40% mobile phase B in 65 min and then to 80% B in an additional 5 min at 300 nl/min. The LTQ-Orbitrap mass spectrometer was operated in a data-dependent mode in which each full MS scan (30 000 resolving power) was followed by five MS/MS scans where the five most abundant molecular ions were dynamically selected and fragmented by collision-induced dissociation using a normalized collision energy of 35% in the LTQ ion trap. Dynamic exclusion was allowed. Tandem mass spectra were searched against the Swissprot human protein database using Mascot (Matrix Science) with no enzyme cleavage (because of the use of the unspecific protease pepsin), static cysteine alkylation by iodoacetamide, and variable nitration of Tyr and methionine oxidation.

Minocycline Samples—All of the minocycline samples were analyzed by LC-MS using an Esquire 3000 mass spectrometer (Bruker Daltonics) and an Agilent 1100 micro-HPLC equipped with a Vydc MS C18 reversed phase column (Grace). After sample injection, the column was washed for 5 min with 90% mobile phase A (0.1% formic acid) and 10% mobile phase B (0.1% formic acid in acetonitrile), and minocycline was eluted using 80% mobile phase B with a flow rate of 50 μl/min. The MS data were acquired in a mass range of m/z = 300 to m/z = 1100.

Statistics—The values are expressed as the means ± S.D. (n = 3). The data were analyzed by one-way ANOVA or Student’s t test as appropriate, and the differences were determined by Bonferroni’s post hoc test (Prism or Origin software). If not otherwise indicated, the means were considered as statistically significant at p < 0.05.

RESULTS

Differential Scavenging of ‘NO versus PON by Minocycline—Anti-inflammatory actions of minocycline have been attributed to its ability to limit the production of ‘NO. Direct interaction of minocycline with ‘NO or PON as a key neurotoxic derivative of ‘NO has not been investigated yet. Here, the PON scavenging properties of minocycline were evaluated by an assay in which the test compound competes with the Sin-1-mediated oxidation of DHR 123 to rhodamine (Fig. 1A). Sin-1 releases ‘NO with a t1/2 of ~45 min and concomitantly generates O2•− in a 1:1 molar ratio. The PON generated under these conditions has a t1/2 of ~1–2 s, so that a steady state PON concentration level of ~0.01% of the applied Sin-1 concentration is established. The PON generated by 50 μM Sin-1 (~5 mM steady state PON) led to a strong oxidation of DHR 123 within 15 min. This oxidation was nearly completely blocked by 50 μM minocycline. A half-maximal inhibition was observed at pharmacologically relevant concentrations of ~5 μM, and even 1 μM minocycline led to a significant reduction of ~30% (Fig. 1A). To validate the assay, the selective PON scavenger uric acid and the general antioxidant ascorbic acid were used and showed inhibitory effects in the same concentration range as minocycline (not shown).

Interaction of minocycline with ‘NO was evaluated by the use of an ‘NO-selective electrode. To exclude false-positive signals, the electrode was tested for its reactivity toward PON, O2•−, ‘OH-generating systems, and dopamine-semiquinones and revealed no significant increase in signal output even at high concentrations (not shown). As ‘NO donor, freshly prepared Spermine-NONOate (t1/2 ~45 min) was added to the system in the presence or absence of minocycline. Even high minocycline concentrations of up to 100 μM did not significantly reduce the ‘NO signal. Thus, a direct interaction of ‘NO with minocycline can be excluded (Fig. 1A). As control, the O2•−-generating system of xanthine oxidase plus its substrate hypoxanthine was added. This led to a concentration-dependent reduction of the ‘NO signal as expected. Under
Minocycline as Scavenger of Peroxynitrite

these conditions, PON is formed that is not detected by the electrode (not shown). To investigate the cellular relevance of these chemical data, the human dopaminergic cell line LUHMES (39) was chosen.

The levels of intracellular GSH were used as redox readout after treatment with the PON donor Sin-1 or the pure NO donor Spermine-NONOate in the presence of various minocycline concentrations. Both treatments lead to a significant decline of reduced GSH within 4 h. Minocycline demonstrated direct antioxidant properties against PON in the 5–25 μM range, whereas no protective effect on NO triggered GSH depletion was observed, even at the highest concentrations of minocycline (Fig. 1B). These initial experiments suggested that minocycline may be a specific PON scavenger rather than a general antioxidant and that this may have relevance in biological systems or diseases.

Specific Peroxynitrite Scavenging by Minocycline—In our initial experiments, PON had been generated by Sin-1. To exclude the possibility that minocycline interfered with the decomposition of this compound and the generation of PON, an alternative system was used. The combination of the NO-releasing compound Spermine-NONOate, and the O$_2^-$ generating enzyme xanthine oxidase allows generation of NO and O$_2^-$ in an almost 1:1 ratio that is necessary for optimal PON formation. Also in this system, minocycline as well as uric acid and ascorbic acid (not shown) scavenged the generated PON (Fig. 2A). As further control, the luminol-derivative L-012 was used as an alternative detection dye instead of DHR 123. L-012 oxidations are relatively specific for PON at the concentrations used here. In combination with Sin-1, minocycline lead to a concentration-dependent decline of L-012 luminescence, whereas tetracycline and gentamicin showed no significant inhibition (Fig. 2B). Experiments with uric acid and ascorbic acid demonstrated a concentration-dependent decline in both detection systems (not shown). The significant difference in the PON scavenging capacity of minocycline and tetracycline may be due to the additional dimethylamino substituent in the phenol ring of minocycline compared with tetracycline. To test this assumption, scavenging experiments were performed with 4-dimethylaminophenol in direct comparison with unsubstituted phenol. 4-Dimethylaminophenol, as part of the minocycline structure, exhibited a significant inhibitory impact in the DHR 123/Sin-1 assay system in the low micromolar range, whereas a significant inhibitory impact of phenol (part of tetracycline structure) was only observed at concentrations of 50 μM and higher (Fig. 2C). Minocycline was also compared with doxycycline and rifampicin. These drugs were better PON scavengers than tetracycline and were able to prevent the oxidation of the DHR-123 indicator compound by PON. They might offer protection in some in vivo models if dosed high enough, but our data indicated that they were still ~100-fold less potent than minocycline (not shown).

Interaction of Minocycline with Other Biologically Relevant Oxygen Radicals—

To confirm the interaction of minocycline with authentic PON in an independent test system, EPR spectroscopy was applied to detect the formation of the stable TEMPOE radical generated by the interaction of the spin trap TEMPONE-H with PON. In this system, minocycline reduced TEMPONE formation as efficiently as the established PON scavenger uric acid, whereas tetracycline or gentamicin had no effect at all in this concentration range (Fig. 3A).

The primary oxygen radical produced under inflammatory conditions is the superoxide anion (O$_2^-$). To investigate an interaction of O$_2^-$ with minocycline, the radical was enzymatically generated by xanthine oxidase and detected by the cytochrome c reduction assay (Fig. 3B). To exclude a contribution of other radical species on cytochrome c reduction, the experiments were performed in the absence or presence of superoxide dismutase (100 units/ml). The difference between these two conditions was used as readout for the O$_2^-$-specific reduction. Although the control compound ascorbic acid lead to a concentration-dependent decline in O$_2^-$-mediated cytochrome c reduction, minocycline had no effect at all in a pharmacologically relevant concentration range (Fig. 3B).

Finally, the interaction of the hydroxyl radical (‘OH) with minocycline was investigated (Fig. 3C). Hydroxyl radicals were generated by a mixture of H$_2$O$_2$ and Fe$^{2+}$ according to the Fenton reaction. As readout, deoxyribose was added to the reaction, which forms degradation products that interact

![Figure 1](https://example.com/figure1.png)

**FIGURE 1. Interaction of minocycline with PON or NO.** A, minocycline, in the concentrations indicated, was preincubated with the PON donor Sin-1 (50 μM), followed by the addition of DHR 123 (1 μM). Rhodamine generated from DHR 123 was detected in a fluorescence reader. Alternatively, minocycline was pretreated with the NO donor Spermine-NONOate (10 μM), and NO was measured by a NO-selective electrode over a period of 100 s. B, human dopaminergic neurons (LUHMES) were exposed to the PON-generating Sin-1 (100 μM) or the NO donor Spermine-NONOate (100 μM) in the presence of various concentrations of minocycline or left untreated (control, contr.). After 4 h, the incubations were terminated by medium removal and lysis of the cells. The amount of protein and GSH were determined in the lysates. The data are expressed as the means ± S.D. of quadruplicate samples. The statistical significance was determined by one-way ANOVA followed by Bonferroni’s post-hoc test. *, p < 0.05 versus 0 μM minocycline.
with thiobarbituric acid to form an optically detectable chromogen. In the pharmacologically relevant concentration range up to 10 μM, neither minocycline nor tetracycline had an impact on the OH-dependent deoxyribose degradation. At concentrations of 50 and 100 μM, a small (10%) but significant inhibition was observed, whereas the known OH radical scavenger Me2SO (positive control) resulted in a significant (20%) inhibition at 5 μM and up to 40% inhibition at 100 μM (Fig. 3C). In conclusion, minocycline did not interact with O2 or NO, whereas it showed weak scavenging of OH and potent reaction with PON.

Decomposition of Minocycline by Peroxynitrite—To investigate PON-mediated modifications of the minocycline molecule, the compound was treated with various concentrations of authentic PON and analyzed by HPLC. A concentration-dependent decline in the minocycline peak was observed (Fig. 4A). For investigations of the specificity of this reaction, minocycline was treated with PON, the PON generator Sin-1, the O2 source KO2, or the OH-generating compound AAPH for 24 h. The remaining minocycline content was quantified by photospectroscopic measurement at 360 nm or by HPLC-based analysis (Fig. 4B). Although KO2 or AAPH treatment hardly lead to a decline, both Sin-1 and PON lead to a significant degradation of minocycline. The HPLC analysis showed no additional peaks as an indicator for a modified minocycline structure. For further analysis, samples of PON-treated minocycline were examined by mass spectrometry. This also demonstrated the disappearance of the minocycline peak (m/z 458.5 Da) and the generation of low levels of multiple reaction products (Fig. 4C). We next investigated the possibility that not the intact minocycline molecule but rather the decomposition products resulting from an initial interaction with PON may be potent PON scavengers. Minocycline (5 μM) was therefore pretreated with increasing concentrations of authentic PON (Fig. 4D). After decomposition of PON, these mixtures were added to a detection system composed of Sin-1 as a source of steady state levels of PON and DHR 123 as readout. The capacity of minocycline to scavenge Sin-1-derived steady state levels of PON was impaired in a concentration-dependent manner when it was pretreated with authentic PON. This strongly suggests that the intact molecule is primarily responsible for the PON scavenging capacity of minocycline (Fig. 4D).

Protection of Biomolecules by Minocycline—To investigate potential bio-protective properties of minocycline, plasmid DNA as model system was treated with a fixed concentration of the PON-generating compound Sin-1 (50 μM). Oxidative DNA lesions (8-oxo-deoxyguanosine) were converted into strand breaks by the enzyme formamidopyrimidine-DNA glycosylase. Strand breaks were then detected by an automated fluorescence detection alkaline DNA unwinding assay. Although gentamicin had no effect at all, tetracycline revealed a moderate but significant effect at the highest concentrations of 10 μM, whereas the PON scavenging capacity of minocy-
Minocycline as Scavenger of Peroxynitrite

A, the spin trap TEMPONE-H (100 μM) was incubated with authentic PON (5 μM) in the presence of 5 μM minocycline, tetracycline, gentamicin, or uric acid to generate the stable TEMPONE-radical detected by EPR spectroscopy. The graphs are representative of three independent experiments. B, minocycline or ascorbic acid as control were added to a system of O2 dependent 2-deoxyribose degradation was photometrically detected after thiobarbituric acid derivatization. The statistical significance was determined by one-way ANOVA followed by Bonferroni’s post-hoc test. *, p < 0.05 versus 0 μM minocycline.

On closer examination of the blots stained for ASYN and 3-NT, it became evident that PON treatment resulted in the partial protection of the DNA from oxidative modifications at concentrations as low as 1 μM reduced this damage (Fig. 5A). As a control, decomposed Sin-1 was added and resulted in no common deletions. The addition of minocycline to the LUKMES cultures after total decomposition of Sin-1 (6 h) for an additional 18 h also had no protective effect on the Sin-1-evoked common deletions (not shown).

Among all of the modifications triggered by PON in biological systems, nitration of tyrosine residues is the best characterized and is frequently used as marker for oxidative and nitrative stress. To test whether minocycline can protect tyrosine, the amino acid was treated with PON in the presence of increasing concentrations of antibiotics. Although tetracycline and gentamicin showed no significant impact on 3-NT formation as detected by ELISA, minocycline inhibited the reaction already at submicromolar concentrations (Fig. 5C).

**Prevention of α-Synuclein Nitration by Minocycline**—A disease-relevant example of a protein that can be tyrosine-nitrated is ASYN. Nitrated ASYN was identified as component of the intracellular proteinaceous deposits found in Parkinson disease brains. To investigate the influence of minocycline on ASYN nitration, purified human wild type ASYN was treated with PON in the presence of varying concentrations of antibiotics or uric acid. The nitration of ASYN was completely prevented by minocycline levels of <1 μM. Uric acid was slightly less potent. Tetracycline partially reduced nitration (by 30–40%) in the range of 10–100 μM, whereas gentamicin was without effect (Fig. 6A). To investigate the protective impact of minocycline on ASYN nitration in a cellular system, HEK 293 cells stably overexpressing Myc tagged human wild type ASYN were preincubated with minocycline or the general antioxidant ascorbic acid and nitrated by authentic PON. The protein was recovered by immunoprecipitation against the Myc tag. Western analysis with staining of ASYN and 3-NT revealed that nitration of ASYN was reduced by the presence of minocycline or ascorbic acid (Fig. 6B).

The presence of minocycline or uric acid limited the formation of ASYN dimer and multimers but was not able to completely prevent their generation (Fig. 7A). Human ASYN contains four tyrosine residues as potential sites for nitrations. For a more detailed view on the tyrosines involved in the 3-NT formation, purified human wild type ASYN was treated with 5 or 50 μM authentic PON. At both concentrations, mass spectrometric analysis of the digested protein revealed a nitration of the tyrosine residues Tyr125, Tyr133, and Tyr139 but not Tyr39. The presence of minocycline completely prevented
the nitration of all three tyrosines. As an additional post-translational modification, sulfoxidation of methionines Met\(^{116}\) and Met\(^{127}\) was observed that, in contrast to the nitration of tyrosines, was not prevented by the presence of minocycline (Fig. 7B). This suggests that different reactive metabolites formed from peroxynitrous acid may cause different modifications and react differently with minocycline. Fig. 7B represents a schematic summary of mass spectrometry data. Detailed information and data can be found in supplemental Fig. S1.

Minocycline Protects Neuronal Cells from PON Treatment—Finally, it was examined whether the direct PON scavenging capacity of minocycline may also be involved in neuroprotection. We used neuronally differentiated LUHMES cells as targets and measured neurite integrity, resazurin reduction, and LDH release as cell death end points (Fig. 8). To exclude that minocycline protected the cells from PON indirectly by blocking death signaling cascades, we made use of the short half-life of authentic PON (\(t_{1/2} = 1–2\) s). When present in the cell culture medium at the time of PON addition (\(\text{Min} \to \text{PON}\)), both minocycline and ascorbic acid protected from cell death according to all different end points even when minocycline was washed out 15 min after PON addition (Fig. 8, A–C). When minocycline or ascorbic acid was added shortly (5 min) after the addition of PON (\(\text{PON} \to \text{Min}\)), no protection was observed. These results strongly suggest that minocycline can protect cells from PON by direct scavenging of this reactive oxygen species.

DISCUSSION

In the present study, we demonstrated that minocycline acts as highly selective scavenger of PON at submicromolar concentrations. This was observed not only in chemically defined assay systems but also in various cellular models, including human neurons. Notably, tetracycline did not show such activity in the low micromolar range, even though it is known that it may scavenge PON in the mM range, similar to most phenolic compounds. No comparative investigations on the interaction of minocycline with biologically relevant radical species have been conducted so far. The high specificity of the antioxidant profile of minocycline is suggested by our findings that the drug interacted neither with \(\text{NO}\) nor with \(\text{O}_2^{-}\) or \(\text{H}_2\text{O}_2\). Interactions with \(\text{OH}\) were observed but were far less pronounced than with PON. The results suggest that a defined target and mechanism of action has been defined for minocycline.

The difference observed for the interaction of minocycline versus tetracycline with PON was not found for the \(\text{OH}\) scavenging capacity of the two antibiotics. This may indicate that the interactions of \(\text{OH}\) and PON with minocycline are based on different mechanisms. After exposure of minocycline to PON, we were not able to detect a hydroxylated or nitrated derivative of minocycline or another chemically defined me-

FIGURE 4. Decomposition of minocycline by PON treatment. A, minocycline (10 \(\mu\)M) was treated with various concentrations of authentic PON. The remaining amount of intact minocycline was quantified by HPLC analysis. B, minocycline (10 \(\mu\)M) was treated with the \(\text{OH}\) generator AAPH, \(\text{KO}_2\) as a source of \(\text{O}_2^\cdot\), the PON donor Sin-1, or authentic PON for 24 h. The samples were investigated both by recording of optical spectra between 200 and 600 nm and by HPLC analysis. For quantitative evaluation of the optical spectra, the values at the absorption maximum of minocycline of 360 nm were used. No alternative peak was observed in the optical spectra or in HPLC analysis. C, minocycline (100 \(\mu\)M) with or without treatment by authentic PON (100 \(\mu\)M) was subjected to LC-MS/MS mass spectrometric analysis. The minocycline peak at 458.5 Da almost completely vanished, and no dominating alternative peak was observed. D, in a first step, minocycline (5 \(\mu\)M) was treated with authentic PON in the concentrations as indicated. The short \(t_{1/2}\) of PON (1–2 s) ensured its complete decomposition within a minute. After 5 min, the pretreated samples were incubated with the PON generator Sin-1 (50 \(\mu\)M) and DHR 123 (1 \(\mu\)M) to test their remaining scavenging capacity. The oxidation of DHR 123 to rhodamine was quantified after 20 min. The statistical significances were determined by one-way ANOVA followed by Bonferroni’s post-hoc test. *, \(p < 0.05\) versus 0 \(\mu\)M minocycline.
Minocycline as scavenger of peroxynitrite

Minocycline demonstrated neuroprotective properties in a variety of chronic neurodegenerative diseases such as Alzheimer disease, Parkinson disease, and amyotrophic lateral sclerosis (6–12). However, no clearly defined molecular target of minocycline action has been described that would explain the wide spectrum of activities of the drug. Our findings that PON is a direct target and chemical interaction partner of minocycline in biological assay systems suggest that this mechanism may be relevant in pathological situations and may contribute to solve the riddle of minocycline action. Neurodegenerative diseases treated with minocycline are all accompanied by an inflammatory activation of glial cells and apoptotic

FIGURE 5. Protection of biological targets by minocycline. A, plasmid DNA was treated with the PON-generating compound Sin-1 (50 μM) in the presence of minocycline, tetracycline, or gentamicin. Following treatment for 4 h, 8-oxo-deoxyguanosine lesions were enzymatically converted into strand breaks that were quantitatively assessed by the fluorimetric detection of alkaline DNA unwinding assay (n = 4). B, LUHMES cells were treated with the PON donor Sin-1 (250 μM) and different concentrations of minocycline for 18 h. Total DNA was isolated and used as template for PCR amplification. The control value (black) indicates cells without Sin-1 treatment. The deletion of a fragment of mitochondrial DNA (common deletion) was evaluated by PCR utilizing settings that allow amplification only when the deletion occurred. Amplification of a stable region of mitochondrial DNA served for standardization. C, tyrosine (5 μM) was treated with authentic PON (5 μM) in the presence of various concentrations of minocycline, tetracycline, or gentamicin. Then 3-nitrotyrosine was quantified by ELISA. All of the reactions were carried out in 100 mM potassium phosphate buffer to ensure constant pH. All of the experiments are expressed as the means ± S.D. of quadruplicate samples. The statistical significances were determined by one-way ANOVA followed by Bonferroni’s post-hoc test. *, p < 0.05 versus 0 μM minocycline.

FIGURE 6. Prevention of ASYN nitration by minocycline. A, purified recombinant human ASYN (0.5 μg/ml) was preincubated for 5 min with minocycline, uric acid, tetracycline, or gentamicin in the concentrations indicated and then treated with PON (5 μM) for 1 min. ASYN nitration was analyzed by Western blot and staining of 3-NT with selective antibodies. Representative blots of three independent experiments are shown. B, HEK 293 cells stably overexpressing Myc-tagged human wild type ASYN were pretreated with minocycline (Mino, 5 μM), ascorbic acid (AA, 50 μM), or left untreated (contr.) for 15 min. Then nitration was performed with authentic PON (100 μM). ASYN was recovered from cell homogenates by immunoprecipitation using an anti-Myc antibody and stained for 3-NT and with an anti-ASYN antibody as loading control (contr.). The experiments were repeated four times, and band intensities were assessed for quantitative evaluations. The values are the means ± S.D. (n = 4). The statistical significances were determined by one-way ANOVA followed by Bonferroni’s post-hoc test. *, p < 0.05 versus 0 μM minocycline.
Minocycline as Scavenger of Peroxynitrite

A

B

Incubation: Summary of mass spectrometric analysis:

| Incubation         | ASYN<sub>35-44</sub> | ASYN<sub>113-140</sub> |
|--------------------|-----------------------|-------------------------|
| control            | EGVLY<sub>0</sub>VGSKT | EDM<sub>0</sub>PDN PSEEGY<sub>0</sub>QDY<sub>0</sub>EPEA   |
| PON [5 μM]         | EGVLY<sub>0</sub>VGSKT | EDM<sub>0</sub>PDN PSEEGY<sub>0</sub>QDY<sub>0</sub>EPEA   |
| PON + Minocycline  | EGVLY<sub>0</sub>VGSKT | EDM<sub>0</sub>PDN PSEEGY<sub>0</sub>QDY<sub>0</sub>EPEA   |

FIGURE 7. Impact of minocycline on the nitration and formation of ASYN multimers. A, human recombinant ASYN (0.5 μg/ml) was nitrated by authentic PON (5 μM) in the presence or absence of minocycline or uric acid and analyzed by Western blotting. Control values (c) received no minocycline, uric acid, or PON treatment. Staining of ASYN or 3-NT indicated the appearance of additional nitrated ASYN bands following PON treatment with a dominating band at ~34 kDa. The quantitative data were obtained from four independent experiments and expressed as the mean ± S.D. B, to identify the nitrated tyrosine residues, recombinant human ASYN (0.5 μg in 1 ml) was treated with PON (5 μM) in the presence or absence of minocycline (5 μM). The experiment was repeated until 25 μg of ASYN/condition had been nitrated. Aliquots were then pooled and concentrated to a volume of 500 μl for pepsin digestion and LC-MS/MS analysis. The human 140-amino acid protein ASYN contains four tyrosine residues located at the positions 39, 125, 133, and 136. In addition to tyrosine nitration, methionine sulfoxidations were observed.

Minocycline as a Scavenger of Pathologically Relevant PON Concentrations—PON at concentrations sufficient to act as oxidant in the brain primarily occurs following inflammatory activation of glial cells (43). Under such conditions, DNA damage or nitration of proteins can be observed in vivo (44, 45). DNA damage was therefore investigated in the present study in a first step by exposure of plasmid DNA to Sin-1-generated fluxes of PON. A concentration-dependent formation of 8-oxo-deoxyguanosine was found and was completely prevented by 5 μM minocycline. This concentration corresponds to the range that can be expected in the brain following repeated standard oral doses of minocycline in clinical studies or animal experiments. The DNA damage was not detected after NO or O<sub>2</sub> treatment (not shown). To study the impact of PON on DNA in intact cells, the deletion of a defined segment of mitochondrial DNA was investigated. Aliquots were then pooled and concentrated to a volume of 500 μl for pepsin digestion and LC-MS/MS analysis. The human 140-amino acid protein ASYN contains four tyrosine residues located at the positions 39, 125, 133, and 136. In addition to tyrosine nitration, methionine sulfoxidations were observed.
not prevent the oxidation of the two methionine residues present in ASYN. Nitration of tyrosine primarily occurs via attack by the NO₂ radical that originates from the decomposition of peroxynitrous acid (47), and minocycline may directly interact with this specific radical. Our findings are consistent with the view that methionine oxidation is mediated by a different radical species. Others reported that OH, as another degradation product of peroxynitrous acid, plays no significant role in methionine oxidation (30). Instead, a two electron oxidation by an interaction with the electrophilic nitrogen of peroxynitrous acid and the sulfur atom of methionine has been proposed and thus could be responsible for the observations made in our study (48, 49). The neutralization of OH may be relevant in pathological situations favoring the Fenton reaction, as for example in the iron-rich substantia nigra in Parkinson disease. The effect of OH scavenging would become pharmacologically relevant only at higher concentrations of minocycline (10⁻¹⁰ M), that are likely to be reached in several animal studies described in the literature (8).

Minocycline as Scavenger of Physiological PON Concentrations—Pathologically high concentrations of PON are usually found under conditions when the inducible isoform of nitric-oxide synthase (NOS-2) is the source of NO. When minocycline is considered as a scavenger of PON in its role as signaling molecule, the question arises regarding how NO is generated in the absence of NOS-2 expression. The significance of the constitutively expressed brain isoform NOS-1 has been underestimated for a long time, although it has been known that NOS-1 contributes to brain damage associated with DNA lesions or PARP activation (45, 50, 51). Recent findings indicated nitration of proteins in activated cells in the absence of inducible NOS-2 (52). NOS-1 activity is mainly regulated by levels of cytosolic free Ca²⁺, and hence, Ca²⁺ becomes a key regulator in the endogenous formation of PON. Glutamate excitotoxicity represents a classical model of elevated cytosolic Ca²⁺ levels (53), and in such models, minocycline concentrations in the low nanomolar range have been reported to be neuroprotective (11). Similar observations were made in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)/1-Methyl-4-phenylpyridinium (MPP⁺) models that are also characterized by disturbed cellular Ca²⁺ homeostasis (54). Further indirect evidence for a role of PON scavenging by minocycline comes from experiments in which cerebellar granule cells were treated with subtoxic concentrations of an NO donor and MPP⁺ that together allow formation of PON (8). In all of these models, minocycline demonstrated neuroprotective effects, and we suggest that at least some of its protective properties may originate from a direct scavenging of the intracellular signaling molecule PON.

In chronic neurodegenerative disorders, PON signaling may be involved in the assembly of the mitochondrial permeability transition pore complex, leading to cytochrome c release (15). Moreover, PON is pivotally involved in the activation of signaling cascades such as p38 MAPK or NF-κB (26,
Minocycline as Scavenger of Peroxynitrite

32, 33). It might therefore be speculated that scavenging of PON contributes to the observations on an inhibition of cytochrome c release as well as the repeatedly described inhibitory effect on the p38 signaling cascade and on induction of pro-inflammatory enzymes such as NOS-2 or COX-2 in glial cells.

In this work, we have demonstrated that minocycline is a selective and potent scavenger of PON. The compound protected cells from exogenously added PON. Under such conditions that, for example, reflect the situation of inflammatory glia activation and its impact on neurons in the brain, relatively high concentrations of the antibiotic in the micromolar range are required to scavenge PON sufficiently fast to achieve protection. In contrast, considering the role of endogenous low levels of PON as intracellular signaling molecules under chronic pathological conditions, and the excellent penetration of biological membranes by minocycline, nanomolar concentrations might be sufficient to interrupt chronic processes that would ultimately lead to cell death.

Acknowledgment—We are particularly thankful to Prof. V. Ullrich for fruitful discussions and careful reading of the manuscript.

REFERENCES

1. Kelly, R. G., and Kanegis, L. A. (1967) Toxicol. Appl. Pharmacol. 11, 171–183
2. Goulden, V., Glass, D., and Cunliffe, W. J. (1996) Br. J. Dermatol. 134, 693–695
3. Saivin, S., and Houin, G. (1988) Clin. Pharmacokinet. 15, 355–366
4. Yong, V. W., Wells, J., Giuliani, F., Casha, S., Power, C., and Metz, L. M. (2004) Lancet Neurol. 3, 744–751
5. Kim, H. S., and Suh, Y. H. (2009) Behav. Brain Res. 196, 168–179
6. Wang, C. X., Yang, T., Noor, R., and Shuaib, A. (2002) BMC Neurosci. 2, 2
7. Kitz, J., Nguyen, M. D., and Julien, J. P. (2002) Neurobiol. Dis. 10, 268–278
8. Du, Y., Ma, Z., Lin, S., Dodel, R. C., Gao, F., Bales, K. R., Triarhou, L. C., Leach, J. K., Le, Y. B., Kim, S. U., and Jin, B. K. (2005) Proc. Natl. Acad. Sci. U.S.A. 92, 1297–1308
9. Chen, M., Ona, V. O., Li, M., Ferrante, R. J., Przedborski, S., Kristal, B. S., and Friedlander, R. M. (2002) Neuron 34, 139–148
10. Wilkins, A., Nikodemova, M., Compston, A., and Duncan, I. (2004) Neurotox. Res. 16, 361–371
11. Bradesi, S., Svensson, C. L., Steinauer, J., Pothoulakis, C., Yaksh, T. L., and Mayer, E. A. (2009) Gastroenterology 136, 1339–1348
12. Tikk, T., Feibich, B. L., Goldsteins, G., Keinanen, R., and Koistinaho, J. (2001) J. Neurosci. 21, 2580–2588
13. Filipovic, R., and Zecevic, N. (2008) Exp. Neurol. 211, 41–51
14. Kraus, R. L., Pasieczny, R., Lariosa-Willingham, K., Turner, M. S., Jiang, A., and Trauger, J. W. (2005) J. Neurochem. 94, 819–827
15. Zuo, S., Stavrakou, I. G., Droza, M., Kim, B. Y., Ona, V., Li, M., Sarang, S., Liu, A. S., Hartley, D. M., Wu, D. C., Gullans, S., Ferrante, R. J., Przedborski, S., Kristal, B. S., and Friedlander, R. M. (2002) Nature 417, 74–78
16. Lin, S., Zhang, Y., Dodel, R., Farlow, M. R., Paul, S. M., and Du, Y. (2001) Neurosci. Lett. 315, 61–64
17. Machado, L. S., Kozak, A., Ergul, A., Hess, D. C., Borlongan, C. V., and Fagan, S. C. (2006) BMC Neurosci. 7, 56
18. Schildknecht, S., Daiber, A., Ghisa, S., Cohen, R. A., and Bachschmid, M. M. (2008) FASEB J. 22, 215–224
19. Falsig, J., van Beek, J., Hermann, C., and Leist, M. (2008) J. Neurosci. Res. 86, 1434–1447
20. Pryor, W. A., Jin, X., and Squadrito, G. L. (1994) Proc. Natl. Acad. Sci. U.S.A. 91, 11173–11177
21. Beckman, J. S. (1996) Chem. Res. Toxicol. 9, 836–844
22. Yakovlev, V. A., Barani, I. I., Rabender, C. S., Black, S. M., Leach, J. K., Graves, P. R., Kellogg, G. E., and Mikkelsen, R. B. (2007) Biochemistry 46, 11671–11683
23. Hope, R. S., Zhang, L., and Song, L. (2000) Arch. Biochem. Biophys. 376, 365–370
24. Hodara, R., Norris, E. H., Giasson, B. I., Mishizen-Eberz, A. J., Lynch, D. R., Lee, V. M., and Ischiropoulos, H. (2004) J. Biol. Chem. 279, 47746–47753
25. Wenzel, P., Schuhmacher, S., Kienhöfer, J., Müller, J., Jope, R. S., Zhang, L., and Song, L. (2000) Proc. Natl. Acad. Sci. U.S.A. 97, 139, 233–240
26. Chen, M., Ona, V. O., Li, M., Ferrante, R. J., Fink, K. B., Zhu, S., Bian, J., Guo, L., Farrell, L. A., Hersch, S. M., Hobbs, W., Vonsattel, J. P., Cha, J. H., and Friedlander, R. M. (2000) Nat. Med. 6, 797–801
27. Yrjänheikki, J., Tikk, T., Keinanen, R., Goldsteins, G., Chan, P. H., and Koistinaho, J. (1999) Proc. Natl. Acad. Sci. U.S.A. 96, 13946–13950
28. Tikk, T. M., and Koistinaho, J. E. (2001) J. Immunol. 166, 7527–7533
29. Brundula, V., Rewcastle, N. B., Metz, L. M., Bernard, C. C., and Yong, V. W. (2002) Brain 125, 1297–1308
30. Gieseler, A., Schultze, A. T., Kupsch, K., Haroon, M. F., Wolf, G., Siemen, D., and Kreutzmann, P. (2009) Biochem. Pharmacol. 77, 888–896
31. Wilkins, A., Nikodemova, M., Compston, A., and Duncan, I. (2004) Neuron Glia Biol. 1, 297–305
32. Brundula, V., Eutamene, D., Cartier, C., Broccardo, M., Improta, G., Houdeau, E., Potrella, C., Ferrier, L., Theodorou, V., and Bueno, L. (2010) Gastroenterology 139, 553–563
33. Kass, G. E., Wright, J. M., Nicotera, P., and Orrenius, S. (1988) Arch. Biochem. Biophys. 260, 789–797